Joy Lin is a freelance travel journalist with a focus on health and pharmaceutical topics, particularly relating to the FDA, Pfizer, Moderna, and the Coronavirus. She often explores the intersection of travel and public health within the context of the European Union. Joy's work has been featured in GeneOnline and Tradeline, Inc.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Joy Lin's coverage focuses on the healthcare and pharmaceutical industries, with an emphasis on press releases and data citations. Her articles predominantly cover FDA approvals, partnerships, licensing agreements, and developments in therapeutic molecules.
For pitching to Joy Lin, consider offering access to exclusive data or insights related to FDA approvals, rare diseases treatments or breakthroughs in therapeutic molecules within the healthcare and pharmaceutical sectors. Sources with expertise in regulatory affairs or clinical trials may find success reaching out to her for commentary.
Since Joy Lin’s geographic focus is not specified but she covers global companies' announcements and activities across different regions of the world it would be beneficial for experts from various geographical locations relevant to health care & pharmaceutical industry can reach out providing their valuable insights into the mentioned topics.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Joy Lin
Moderna has entered a partnership with Generation Bio to combine their technologies and develop lipid nanoparticles using Generation Bio’s stealth cell-targeted lipid nanoparticle (ctLNP) delivery system. The collaboration is expected to advance the companies' respective pipelines of non-viral genetic medicines.
By: Joy Lin
Netherlands-based Pharming has announced the US FDA approval of Joenja (leniolisib) to treat activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in patients aged 12 and older.
By: Joy Lin
Novartis has announced positive topline results from a Phase 3 trial of Kisqali (ribociclib) in early breast cancer.
Drug giant GlaxoSmithKline (GSK) is licensing Scynexis’ Brexafemme (ibrexafungerp tablets) in a deal valued at nearly $600 million.
By: Joy Lin
Taiwan’s Bora Pharmaceuticals and South Korea’s Celltrion Asia Pacific Pte, a subsidiary of Celltrion Group Inc, have announced a partnership to contract manufacture and bring to market a range of oral dosage form drugs (OSD) across the Asia-Pacific region.
GSK has announced the US FDA approval of Arexvy, a vaccine against respiratory syncytial virus (RSV), making it the first vaccine of its kind to be approved in the world.
German drugmaker Boehringer Ingelheim is partnering with University of Sydney spinout Kinoxis Therapeutics to develop oxytocin-targeting treatments for people living with psychiatric disorders.
By: Joy Lin
Boston-based Ginkgo Bioworks is entering a new partnership with German drugmaker Boehringer Ingelheim to discover therapeutic molecules that could treat diseases that are considered “out of reach” by conventional drug discovery.
By: Joy Lin
Shanghai-based Rona Therapeutics is collaborating with fellow Chinese company Keymed Biosciences to advance small interfering RNA (siRNA) therapeutics for glomerulonephritis, a type of inflammatory kidney disease.
By: Joy Lin
Campus Incorporates More Active Learning Spaces to Help Prepare Students for the Workplace Published 7/3/2024
(833) 317-6278 
